The calcium-channel blocker controversy: Historical perspective and important lessons for future pharmacotherapies. An international society of pharmacoepidemiology 'Hot topic'

Jorge Kizer, Stephen E. Kimmel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Reports of adverse events in association with calcium-channel blockers led to heated controversy over the safety and efficacy of these drugs, as well as to panic among the general public. At the 1998 International Conference of Pharmacoepidemiology, four experts were asked to summarize, and draw lessons from, the controversy's development. We conducted our own review in order to provide a broader historical perspective on the subject and to present the discussants' views within the framework of additional published opinions. Several years after the controversy's onset, many uncertainties still remain about the merits of CCBs. Yet the media scare generated by a few studies might have been prevented had investigators placed greater emphasis, particularly in their reports to the media, on the limitations of their observational and meta-analytic designs. These studies, however, did call attention to the persistent use of CCBs for off-label indications, and the imperative to improve clinician prescribing practices. Moreover, they showed the pitfalls of reliance on surrogate endpoints, stressing the need for data on major clinical outcomes - with funding a responsibility of the pharmaceutical industry before approving drugs destined for widespread, long-term use. Attention to these lessons will do us well as we evaluate emerging pharmacotherapies. Copyright (C) 2000 John Wiley and Sons, Ltd.

Original languageEnglish (US)
Pages (from-to)25-36
Number of pages12
JournalPharmacoepidemiology and Drug Safety
Volume9
Issue number1
DOIs
StatePublished - Jan 2000
Externally publishedYes

Fingerprint

Pharmacoepidemiology
Calcium Channel Blockers
Off-Label Use
Drug Therapy
Panic
Drug Industry
Pharmaceutical Preparations
Uncertainty
Biomarkers
Research Personnel
Safety

Keywords

  • Calcium-channel blockers
  • Cancer
  • Controversy
  • Coronary artery disease
  • Hemorrhage
  • Hypertension
  • Suicide

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{fb41a4b989114b9f94eedff3f3cbacfa,
title = "The calcium-channel blocker controversy: Historical perspective and important lessons for future pharmacotherapies. An international society of pharmacoepidemiology 'Hot topic'",
abstract = "Reports of adverse events in association with calcium-channel blockers led to heated controversy over the safety and efficacy of these drugs, as well as to panic among the general public. At the 1998 International Conference of Pharmacoepidemiology, four experts were asked to summarize, and draw lessons from, the controversy's development. We conducted our own review in order to provide a broader historical perspective on the subject and to present the discussants' views within the framework of additional published opinions. Several years after the controversy's onset, many uncertainties still remain about the merits of CCBs. Yet the media scare generated by a few studies might have been prevented had investigators placed greater emphasis, particularly in their reports to the media, on the limitations of their observational and meta-analytic designs. These studies, however, did call attention to the persistent use of CCBs for off-label indications, and the imperative to improve clinician prescribing practices. Moreover, they showed the pitfalls of reliance on surrogate endpoints, stressing the need for data on major clinical outcomes - with funding a responsibility of the pharmaceutical industry before approving drugs destined for widespread, long-term use. Attention to these lessons will do us well as we evaluate emerging pharmacotherapies. Copyright (C) 2000 John Wiley and Sons, Ltd.",
keywords = "Calcium-channel blockers, Cancer, Controversy, Coronary artery disease, Hemorrhage, Hypertension, Suicide",
author = "Jorge Kizer and Kimmel, {Stephen E.}",
year = "2000",
month = "1",
doi = "10.1002/(SICI)1099-1557(200001/02)9:1<25::AID-PDS469>3.0.CO;2-E",
language = "English (US)",
volume = "9",
pages = "25--36",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - The calcium-channel blocker controversy

T2 - Historical perspective and important lessons for future pharmacotherapies. An international society of pharmacoepidemiology 'Hot topic'

AU - Kizer, Jorge

AU - Kimmel, Stephen E.

PY - 2000/1

Y1 - 2000/1

N2 - Reports of adverse events in association with calcium-channel blockers led to heated controversy over the safety and efficacy of these drugs, as well as to panic among the general public. At the 1998 International Conference of Pharmacoepidemiology, four experts were asked to summarize, and draw lessons from, the controversy's development. We conducted our own review in order to provide a broader historical perspective on the subject and to present the discussants' views within the framework of additional published opinions. Several years after the controversy's onset, many uncertainties still remain about the merits of CCBs. Yet the media scare generated by a few studies might have been prevented had investigators placed greater emphasis, particularly in their reports to the media, on the limitations of their observational and meta-analytic designs. These studies, however, did call attention to the persistent use of CCBs for off-label indications, and the imperative to improve clinician prescribing practices. Moreover, they showed the pitfalls of reliance on surrogate endpoints, stressing the need for data on major clinical outcomes - with funding a responsibility of the pharmaceutical industry before approving drugs destined for widespread, long-term use. Attention to these lessons will do us well as we evaluate emerging pharmacotherapies. Copyright (C) 2000 John Wiley and Sons, Ltd.

AB - Reports of adverse events in association with calcium-channel blockers led to heated controversy over the safety and efficacy of these drugs, as well as to panic among the general public. At the 1998 International Conference of Pharmacoepidemiology, four experts were asked to summarize, and draw lessons from, the controversy's development. We conducted our own review in order to provide a broader historical perspective on the subject and to present the discussants' views within the framework of additional published opinions. Several years after the controversy's onset, many uncertainties still remain about the merits of CCBs. Yet the media scare generated by a few studies might have been prevented had investigators placed greater emphasis, particularly in their reports to the media, on the limitations of their observational and meta-analytic designs. These studies, however, did call attention to the persistent use of CCBs for off-label indications, and the imperative to improve clinician prescribing practices. Moreover, they showed the pitfalls of reliance on surrogate endpoints, stressing the need for data on major clinical outcomes - with funding a responsibility of the pharmaceutical industry before approving drugs destined for widespread, long-term use. Attention to these lessons will do us well as we evaluate emerging pharmacotherapies. Copyright (C) 2000 John Wiley and Sons, Ltd.

KW - Calcium-channel blockers

KW - Cancer

KW - Controversy

KW - Coronary artery disease

KW - Hemorrhage

KW - Hypertension

KW - Suicide

UR - http://www.scopus.com/inward/record.url?scp=0034069325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034069325&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-1557(200001/02)9:1<25::AID-PDS469>3.0.CO;2-E

DO - 10.1002/(SICI)1099-1557(200001/02)9:1<25::AID-PDS469>3.0.CO;2-E

M3 - Article

C2 - 19025799

AN - SCOPUS:0034069325

VL - 9

SP - 25

EP - 36

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 1

ER -